GIM
CLDI icon

Grassi Investment Management’s Calidi Biotherapeutics CLDI Stock Holding History

Grassi Investment Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$2K Hold
52
– – ﹤0.01% 128
2025
Q1 		$6K Hold
52
– – ﹤0.01% 122
2024
Q4 		$11K Buy
+52
New +$15.6K ﹤0.01% 130

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grassi Investment Management's CLDI Position: Q2 2025 in Review

Grassi Investment Management held its Calidi Biotherapeutics (CLDI) position steady in Q2 2025 at 52 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #128.

Grassi Investment Management first reported a position in CLDI in Q4 2024 and has held it in 3 quarters since. The position peaked at $11K in Q4 2024. 34 funds tracked by Wall St. Rank hold CLDI as of Q2 2025.

  • Grassi Investment Management held 52 shares of Calidi Biotherapeutics worth $2K as of Q2 2025.
  • Grassi Investment Management left its Calidi Biotherapeutics share count unchanged in Q2 2025.
  • Calidi Biotherapeutics made up ﹤0.01% of Grassi Investment Management's portfolio in Q2 2025, its #128 holding.
  • Grassi Investment Management first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 3 quarters since.
  • Grassi Investment Management's Calidi Biotherapeutics position peaked at $11K in Q4 2024.
  • 34 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2025.

Based on Grassi Investment Management's 13F filing for Q2 2025, filed 21 Jul 2025.